Novo Nordisk Expands Access to Wegovy through Telehealth Partners
Novo Nordisk announced on Tuesday it will distribute its weight loss drug, Wegovy, via telemedicine platforms like Hims & Hers, Ro, and Life MD, enhancing patient access now that supply levels in the U.S. have stabilized.
The announcement caused Hims & Hers stocks to surge by 40% in pre-trading on Tuesday, while Novo Nordisk shares experienced a 3% uptick.
With restrictions tightening on pharmacy-compounded versions of Wegovy, Novo Nordisk is eager to capture the market's patient base, previously reliant on these unapproved alternatives.
Telehealth Partnerships Enhancing Accessibility
Dave Moore, heading U.S. operations for the Danish firm, highlighted the importance of partnering with telehealth services to ensure smooth access to the officially branded Wegovy, as compounded alternatives become scarce.
"Seeing the significant interest in obtaining branded Wegovy is encouraging, as it helps transition patients away from compounded services," Moore emphasized.
These collaborations mean patients have seamless access to Wegovy through direct delivery to their homes, making obtaining prescriptions vastly easier.
Flexible Pricing and Supportive Services
A new direct-to-consumer online pharmacy offers Wegovy at approximately $499 monthly for those without insurance, a notable reduction from the standard list price.
However, telehealth providers may set higher prices due to supplementary services incorporated, as mentioned by a Novo Nordisk representative.
Hims & Hers has committed to providing the drug, along with 24/7 care options and dietary support, at $599 for eligible cash-paying users, adding value through extended clinical assistance.
Navigating Pharmaceutical Regulations and Patient Needs
Hims & Hers recently announced they would offer Wegovy and other related medications, although they clarified that some partnerships remain without official endorsement.
Despite having previously dispensed compounded versions of semaglutide, company head Andrew Dudum emphasized their dedication to patient rights amid regulatory shifts.
Compounding is permitted under strict conditions, typically when necessary for patients with specific medical needs, despite pressure from drugmakers to limit such practices due to lack of FDA approval.
Federal deadlines have been set for compounding pharmacies to halt production of semaglutide without prescriptions, ensuring compliance with pharmaceutical regulations in protecting patient interests.




Leave a Reply